Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19

Inclusion Criteria: * Inclusion Criteria: * 18 years and above. * COVID-19 infection Confirmed with a laboratory SARS-CoV-2 RT-PCR nasal swab or antigen test. COVID-19 test specimen must be collected 48 hours prior to Screenings. * Mild COVID-19 Infection defined as: * No Pneumonia (negative by chest auscultation or Chest X Ray). * No Shortness of breath. * No Tachypnea (respiratory rate \<20 breathes/min) * No Hypoxia (Oxygen saturation \>93% on RA) * Fever \<38 degrees. * No Chest Pain. * No Mental Status Change. * Asymptomatic participants must be high risk defined as (any of the following): * Smokers (at least 5 cigarettes per day) * BMI (\> 40 kg/m2) * History of cardiac or chronic lung disease * Clotting predisposing conditions (hemophilia, von Willebrand's disease) * Sickle cell disease * Immunocompromised such as HIV , cancer , on immunosuppressant medications Exclusion Criteria: * Participants diagnosed with another (non-COVID-19) respiratory infection. * Participants with a current tracheostomy or laryngectomy. * Participants who are receiving concomitant respiratory therapy such as oxygen, positive airway pressure or ventilatory support. NOTE: Positive airway pressure for obstructive sleep apnea is permitted if the treatment was established with good compliance for at least 3 months before study enrollment. * Participants with newly diagnosed illnesses that are not deemed stable by the participant's primary care physician), based on I…